Defining molecular targets to prevent alzheimer disease

Archives of Neurology

Volumn 62, Issue 2, 2005, Pages 192-195

  Selkoe, Dennis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE INHIBITOR; DNA; GAMMA SECRETASE INHIBITOR; IBUPROFEN; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOMEDICINE; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; CYTOLOGY; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MISSENSE MUTATION; MOLECULAR GENETICS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPINOCEREBELLAR DEGENERATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOTECHNOLOGY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; TAU PROTEINS;

EID: 13444293174     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.2.192     Document Type: Review

References (19)

1. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-890.
2. Kang J, Lemaire H-G, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733-736.
3. Haass C, Schlossmacher M, Hung AY, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322-325.
4. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159.
5. Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.
6. Bertram L, Tanzi RE Alzheimer's disease: one disorder, too many genes? Hum Mol Genet. 2004;13:R135-R141. Spec No 1.14764623.
7. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
8. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:2892-2897.
9. Sherrington R, Rogaev El, Liang Y, et al. Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature. 1995;375:754-760.
10. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973-977.
11. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
12. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 1999;398:513-517.
13. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487-1491.
14. Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science. 2000;290:150-153.
15. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
16. Selkoe DJ, Schenk D Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. In: Cho AK, Blaschke TF, Insel PA, Loh HH, eds. Annual Review of Pharmacology and Toxicology. Vol 43. Palo Alto, Calif: Annual Reviews Inc; 2003;545-584.
17. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547-554.
18. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol. 2000;48:567-579.
19. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.